New radiation strategy before brain surgery shows promise
NCT ID NCT04503772
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested giving a precise, high-dose radiation treatment (stereotactic radiosurgery) to brain metastases before surgical removal. The goal was to see if this approach improves local control at 6 months. The trial enrolled 70 adults with up to 4 brain metastases from certain cancers. Participants received radiation followed by surgery within 3 days.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- stereotactic radiosurgery (SRS)
- What this could lead to
- If successful, this approach could reduce the chance of brain metastases returning after surgery.
- What could go wrong
- This is a small, non-randomized phase 2 study, so results may not be definitive. Risks include radiation side effects and the possibility that the treatment does not improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
70 people
The number who actually took part.
- Started
-
Feb 2021
- Finished
-
Nov 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * ≤ 4 distinct brain metastases, one with surgical indication * Diagnosis of primary histologically proven breast, digestive or non-small cells lung cancer * ≤ 5 cm larger diameter * Karnofsky performance status ≥ 70 * No contraindication for MRI * Possibility for the patient to be treat with both surgery and stereotactic radiotherapy * ≥ 18 years old * Estimated overall survival ≥ 6 months according to diagnosis specific - graded prognostic assessment (DS GPA) * Written inform consent signed * Affiliation to the French social security system * For women of childbearing age including those on luteinizing hormone-releasing hormone (LH-RH) agonists for ovarian suppression: inclusion negative serum pregnancy test (≤ 7 days prior to the start of preoperative stereotactic radiosurgery (SRS). Exclusion Criteria: * Lymphoma, leukaemia, multiple myeloma, germinal tumours or cerebral primary cancer * Metastases from small-cells lung cancer, kidney cancer, melanoma or sarcoma * Mass effect with deflection ≥ 5 mm from median line or hydrocephaly or compression 4th ventricle, patient neurologically unstable, need for emergency decompressive surgery * \> 4 brain metastases * Contraindication to anaesthesia, MRI or gadolinium injection * Proximity of the tumour with organs at risk which do not allow the prescribed dose to be reached in the envelope * Pregnant or breastfeeding woman * Anti vascular endothelial growth factor (VEGF) within 6 weeks before treatment * Documented leptomeningeal injury * History of irradiation of the encephalon in toto * History of stereotactic radiotherapy on metastasis to be operated on * Non-candidate patient for surgery * Surgical delay \> 3 days compared to stereotactic radiotherapy * Estimated survival \< 6 months by DS GPA * Patient under guardianship or curators * Psychological disorder (cognitive disorders, mental alertness, etc.) or social (deprivation of liberty by judicial or administrative decision) or geographical reasons that may compromise medical monitoring of the trial or compliance with treatment * Woman of childbearing age without effective contraception * Patient participating in another intervention study within 4 weeks prior to inclusion
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Brain metastases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Grenoble Alpes
Grenoble, 38700, France
-
Centre Hospitalier d'Annecy-Genevois
Metz-Tessy, 74370, France
-
Centre Jean PERRIN
Clermont-Ferrand, Puy-de-Dôme, 63800, France
-
Centre Léon BÉRARD
Lyon, 69373, France
-
Hospices Civils de Lyon
Lyon, 69002, France
-
Institut de Cancérologie de l'Ouest
Saint-Herblain, France
-
Institut de cancérologie Strasbourg Europe (ICANS)
Strasbourg, 67000, France
-
Institut de cancérologie de la Loire Lucien Neuwirth
Saint-Priest-en-Jarez, 42270, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can doctors watch brain metastases instead of zapping them?
- Starving brain tumors of blood before surgery
- Tiny gadolinium particles aim to make brain radiation hit harder
- A sharper MRI could reveal radiation sensitivity of brain tumors
- Expert tumor board may extend survival in brain metastases
- Can a new pill outsmart lung cancer in the brain?